First Time in Human Study Using GSK2330672

• Status: Completed
• Trial end date: 2011-09-09
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to look at the safety and tolerability of increasing single doses of GSK2330672 in healthy volunteers.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• healthy volunteer

• 18-60 yrs of age

• for subjects age 50 and above: negative fecal occult blood test within 3 months prior to expected start of dosing, and normal results from sigmoidoscopy or colonoscopy within 5 yrs prior to dosing.

• if female, must be of non-childbearing potential

Exclusion Criteria:

• pregnant or breastfeeding females

• positive HIV

• positive Hep B, or Hep C within 3 months of screening

• positive drugs of abuse screening

• triglycerides > 250 mg/dL

• current or chronic history of liver disease

• any gastrointestinal or gastrointestinal related conditions that could affect fat or bile acid reabsorption

• pancreatitis

• colon cancer or 1st degree relative who has had colon cancer

• abnormal lung function tests

• inability to perform lung function tests

• unwilling to abstain from smoking, alcohol, caffeine, illicit drugs as directed by the site staff

• exposure to more than 4 new chemical entities in the 12 months prior to the first dosing day.

• where participation in the study would results in donation of more than approximately 550mL of blood in a 56-day period.